NASDAQ:CGTX Cognition Therapeutics (CGTX) Stock Price, News & Analysis → This Apple-like Innovator is Revolutionizing Healthcare (From Wall Street Star) (Ad) Free CGTX Stock Alerts $2.10 +0.14 (+7.14%) (As of 05/20/2024 ET) Add Compare Share Share Today's Range$1.96▼$2.1650-Day Range$1.78▼$2.1052-Week Range$0.90▼$3.49Volume128,521 shsAverage Volume93,639 shsMarket Capitalization$84.13 millionP/E RatioN/ADividend YieldN/APrice Target$6.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Cognition Therapeutics alerts: Email Address Cognition Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside217.5% Upside$6.67 Price TargetShort InterestHealthy0.56% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingAcquiring Shares$9,975 Bought Last QuarterProj. Earnings GrowthDecreasingFrom ($0.98) to ($1.40) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.67 out of 5 starsMedical Sector428th out of 917 stocksBiotechnology Industry4th out of 17 stocks 3.5 Analyst's Opinion Consensus RatingCognition Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCognition Therapeutics has only been the subject of 2 research reports in the past 90 days.Read more about Cognition Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.56% of the float of Cognition Therapeutics has been sold short.Short Interest Ratio / Days to CoverCognition Therapeutics has a short interest ratio ("days to cover") of 0.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cognition Therapeutics has recently decreased by 21.79%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCognition Therapeutics does not currently pay a dividend.Dividend GrowthCognition Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for CGTX. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 1 people have searched for CGTX on MarketBeat in the last 30 days. This is a decrease of -80% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cognition Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cognition Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $9,975.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders20.75% of the stock of Cognition Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions43.35% of the stock of Cognition Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Cognition Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Cognition Therapeutics are expected to decrease in the coming year, from ($0.98) to ($1.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cognition Therapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cognition Therapeutics is -2.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCognition Therapeutics has a P/B Ratio of 2.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cognition Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Wall Street StarThis Apple-like Innovator is Revolutionizing HealthcareAI has infiltrated so many sectors, it's sent the demand for AI-friendly GPU computer chips rocketing. Nvidia has gone up more than 3x in the past year. It is now valued well over $2 trillion, making it one of the largest companies in the world.Click here to learn more about the booming eHealth industry About Cognition Therapeutics Stock (NASDAQ:CGTX)Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.Read More CGTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CGTX Stock News HeadlinesMay 21 at 7:30 AM | globenewswire.comCognition Therapeutics Releases New Episode of “Conversations” Podcast: Protecting the Synapse from Amyloid Toxicity in Alzheimer's DiseaseMay 7, 2024 | finanznachrichten.deCognition Therapeutics, Inc.: Cognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business UpdateMay 7, 2024 | markets.businessinsider.comCognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business UpdateMay 7, 2024 | globenewswire.comCognition Therapeutics Reports Financial Results for the First Quarter 2024 and Provides Business UpdateApril 29, 2024 | finance.yahoo.comCognition Therapeutics Completes Enrollment in Phase 2 SHIMMER Study of CT1812 in Mild-to-Moderate Dementia with Lewy BodiesApril 22, 2024 | finance.yahoo.comCognition Therapeutics KOL Event Provided Platform for Valuable Discussion of Current Therapeutic Options and Need for Additional Options to Treat Alzheimer’s DiseaseApril 2, 2024 | globenewswire.comCognition Therapeutics to Present at the Needham Virtual Healthcare ConferenceApril 1, 2024 | finance.yahoo.comCognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer’s Disease on April 12, 2024April 1, 2024 | globenewswire.comCognition Therapeutics to host Virtual KOL Event on the Evolving Landscape in Alzheimer's Disease on April 12, 2024March 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cognition Therapeutics Amid Promising CT1812 Clinical TrialsMarch 27, 2024 | finance.yahoo.comCognition Therapeutics, Inc. (NASDAQ:CGTX) Q4 2023 Earnings Call TranscriptMarch 26, 2024 | globenewswire.comCognition Therapeutics Reports Year End 2023 Financial Results and Provides Business UpdateMarch 26, 2024 | benzinga.comA Preview Of Cognition Therapeutics's EarningsMarch 15, 2024 | globenewswire.comCognition Therapeutics to Report Fourth Quarter and Full Year 2023 ResultsMarch 14, 2024 | globenewswire.comCognition Therapeutics Announces Closing of $11.5 Million Public Offering of Common StockMarch 12, 2024 | markets.businessinsider.comCognition Therapeutics Prices Public Offering Of About 6.57 Mln Shares At $1.75/shrMarch 12, 2024 | msn.comCognition Therapeutics announces pricing of stock offering to raise $11.5MMarch 11, 2024 | msn.comGiants GM Joe Schoen swings big in trade, blockbuster contract for Panthers pass rusher Brian Burns while losing Xavier McKinneyMarch 11, 2024 | globenewswire.comCognition Therapeutics Announces Pricing of $11.5 Million Public Offering of Common StockMarch 11, 2024 | globenewswire.comCognition Therapeutics Announces Proposed Public Offering of Common StockMarch 6, 2024 | finance.yahoo.comCognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer’s Disease StudiesMarch 6, 2024 | globenewswire.comCognition Therapeutics Presents Analyses at AD/PD™ 2024 Correlating Proteomic Findings with Treatment Effect of CT1812 in Alzheimer's Disease StudiesFebruary 26, 2024 | globenewswire.comCognition Therapeutics to Present at the TD Cowen Health Care ConferenceFebruary 22, 2024 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Olema Pharmaceuticals (OLMA), IDEAYA Biosciences (IDYA)February 6, 2024 | finanznachrichten.deCognition Therapeutics, Inc.: New Publication Identifies Key Proteins Involved in Amyloid Oligomer Binding and Supports Mechanism of CT1812See More Headlines Receive CGTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cognition Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/26/2024Today5/21/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:CGTX CUSIPN/A CIK1455365 Webwww.cogrx.com Phone412-481-2210FaxN/AEmployees25Year FoundedN/APrice Target and Rating Average Stock Price Target$6.67 High Stock Price Target$9.00 Low Stock Price Target$5.00 Potential Upside/Downside+217.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.92) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-25,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-98.65% Return on Assets-73.41% Debt Debt-to-Equity RatioN/A Current Ratio4.00 Quick Ratio4.00 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.76 per share Price / Book2.76Miscellaneous Outstanding Shares40,060,000Free Float31,746,000Market Cap$84.13 million OptionableNot Optionable Beta1.54 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesMs. Lisa Ricciardi (Age 64)CEO, President & Director Comp: $854.15kMr. John Brendan Doyle (Age 47)Chief Financial Officer Comp: $414.88kDr. Anthony O. Caggiano M.D. (Age 54)Ph.D., Chief Medical Officer and Head of R&D Comp: $616.27kDr. Steven A. Weissman Ph.D.VP & Head of CMCKey CompetitorsPrecision BioSciencesNASDAQ:DTILElutiaNASDAQ:ELUTInstil BioNASDAQ:TILJATT AcquisitionNYSE:JATTGritstone bioNASDAQ:GRTSView All CompetitorsInsiders & InstitutionsAWM Investment Company Inc.Bought 650,000 shares on 5/16/2024Ownership: 1.623%Levin Capital Strategies L.P.Bought 30,000 shares on 5/16/2024Ownership: 0.075%Carlson Capital L PSold 24,005 shares on 5/14/2024Ownership: 0.534%CM Management LLCBought 175,000 shares on 5/14/2024Ownership: 0.437%Tocqueville Asset Management L.P.Bought 26,000 shares on 5/10/2024Ownership: 0.065%View All Insider TransactionsView All Institutional Transactions CGTX Stock Analysis - Frequently Asked Questions Should I buy or sell Cognition Therapeutics stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cognition Therapeutics in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CGTX shares. View CGTX analyst ratings or view top-rated stocks. What is Cognition Therapeutics' stock price target for 2024? 3 brokers have issued 12-month price objectives for Cognition Therapeutics' shares. Their CGTX share price targets range from $5.00 to $9.00. On average, they predict the company's stock price to reach $6.67 in the next year. This suggests a possible upside of 217.5% from the stock's current price. View analysts price targets for CGTX or view top-rated stocks among Wall Street analysts. How have CGTX shares performed in 2024? Cognition Therapeutics' stock was trading at $1.85 at the beginning of the year. Since then, CGTX stock has increased by 13.5% and is now trading at $2.10. View the best growth stocks for 2024 here. When is Cognition Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, August 13th 2024. View our CGTX earnings forecast. How were Cognition Therapeutics' earnings last quarter? Cognition Therapeutics, Inc. (NASDAQ:CGTX) announced its earnings results on Tuesday, March, 26th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.11. When did Cognition Therapeutics IPO? Cognition Therapeutics (CGTX) raised $45 million in an initial public offering (IPO) on Friday, October 8th 2021. The company issued 3,768,116 shares at a price of $11.00-$13.00 per share. Who are Cognition Therapeutics' major shareholders? Cognition Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include AWM Investment Company Inc. (1.62%), Hohimer Wealth Management LLC (0.56%), Carlson Capital L P (0.53%), CM Management LLC (0.44%), Levin Capital Strategies L.P. (0.07%) and Tocqueville Asset Management L.P. (0.06%). Insiders that own company stock include Ellen B Richstone, Lisa Ricciardi and Peggy Wallace. View institutional ownership trends. How do I buy shares of Cognition Therapeutics? Shares of CGTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CGTX) was last updated on 5/21/2024 by MarketBeat.com Staff From Our PartnersDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDoes this make you sick?Allegiance Gold[FREE Ticket] 27 Crypto Experts Reveal Their #1 Picks Crypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersBill Gates is all about this tiny $2 stockTimothy SykesThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldThe #1 Crypto for AIWeiss Ratings Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cognition Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
